State of Tennessee Department of Treasury Sells 3,129 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

State of Tennessee Department of Treasury lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,086 shares of the medical equipment provider's stock after selling 3,129 shares during the quarter. State of Tennessee Department of Treasury's holdings in Zimmer Biomet were worth $8,988,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its position in shares of Zimmer Biomet by 7.7% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 6,196 shares of the medical equipment provider's stock worth $669,000 after buying an additional 442 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its position in Zimmer Biomet by 17.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider's stock worth $260,000 after purchasing an additional 358 shares during the period. GAMMA Investing LLC boosted its stake in Zimmer Biomet by 67.6% during the 4th quarter. GAMMA Investing LLC now owns 2,298 shares of the medical equipment provider's stock valued at $243,000 after purchasing an additional 927 shares in the last quarter. Central Pacific Bank Trust Division raised its stake in shares of Zimmer Biomet by 7.4% in the 4th quarter. Central Pacific Bank Trust Division now owns 14,525 shares of the medical equipment provider's stock worth $1,534,000 after buying an additional 1,000 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Zimmer Biomet by 3.9% in the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider's stock valued at $1,732,000 after buying an additional 609 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

ZBH traded down $0.04 during trading on Friday, hitting $101.46. The stock had a trading volume of 1,661,962 shares, compared to its average volume of 1,669,704. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12 month low of $93.10 and a 12 month high of $123.96. The company has a 50 day simple moving average of $105.81 and a 200-day simple moving average of $106.59. The firm has a market cap of $20.07 billion, a PE ratio of 22.80, a P/E/G ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company posted $2.20 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.70% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZBH. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.